Aquavit Pharmaceuticals

What Aquavit Pharmaceuticals does

Aquavit Pharmaceuticals is a privately held biotechnology company founded in October 2010 and headquartered in New York City. It develops and commercializes a patented microchannel drug delivery platform (PITO-001) that creates painless intradermal microchannels for administering drugs, biologics, neurotoxins, vaccines, and other therapeutics. The company's commercial anchor is AQUAGOLD® fine touch (AQT-001), a microchannel mesotherapy device delivering approximately 2,000 microinjections per minute and sold directly to aesthetic physicians, dermatologists, and plastic surgeons in B2B channels across more than 50 countries. The portfolio extends through APOLLO® (an AI-integrated smart desktop compounding platform with a big data backend), AQUABELO™ hyaluronic acid crystal technology, and a clinical pipeline spanning botulinum toxin formulations (DTX-021, Dermatox™, DTX-023, DTX-024), periorbital microinjectors (Microtox™, iMicrotox™), an epidermal vaccine delivery device (AQV-1122), and a skin cancer delivery platform (ACK-122/BCC-903).

Revenue is generated through three streams: commercial product sales (primarily AQUAGOLD® devices and consumables sold to medical professionals), licensing and royalty arrangements (including exclusive in-licensing of DTX-021 for the US and Canada), and pre-commercial pharmaceutical pipeline products expected to launch following FDA clearance. Distribution runs through direct enterprise field sales targeting key opinion leaders and clinical investigators, complemented by participation in major industry events (ASDS, AAD, IMCAS, ISAPS, BIO, JP Morgan Healthcare Conference). Manufacturing footprint includes two GMP facilities acquired in 2017 and 2019, plus a Daegu, South Korea facility established in 2014 with Kyungbuk University.

The company holds over 30 patents and 25+ trademarks globally, has received multiple FDA IND clearances, and is pursuing the first-ever FDA approval for intradermal injection of botulinum toxin for skin quality improvement and hyperhidrosis. In September 2025 Aquavit completed two acquisitions (Axon Technologies AG and Genève Technologies) intended to integrate AI and life-science capabilities into its delivery platform. Leadership comprises Sobin Chang (CEO), Dr. Churlsu Kwon (CMO), and Dr. David Shafer (CMTO).

Name

Aquavit Pharmaceuticals

Legal name

Aquavit Pharmaceuticals, Inc.

Website

http://www.aquavitpharma.com

Company type

Private

Founded year

2010

Operating status

Operating

Headcount range

11–50 employees

Short description

Aquavit Pharmaceuticals is a privately held New York-based biotechnology company that develops and commercializes a patented microchannel drug delivery platform, selling the AQUAGOLD® device and a clinical pipeline of intradermal botulinum toxin, vaccine, and dermatology products to aesthetic physicians and dermatologists globally.

Ownership category

akta.pro rank

Product category

Medical Aesthetics & Pharmaceutical Drug Delivery

NAICS

Surgical Appliance and Supplies Manufacturing (339113), Medical Equipment and Supplies Manufacturing (3391)

SIC

Surgical & Medical Instruments & Apparatus (3841), Pharmaceutical Preparations (2834)

akta.pro primary industry

Specialty Injectable & Infusion Therapies (Cross-therapeutic) (HLAIACAO)

akta.pro secondary industries

Vaccine Delivery & Administration Systems (needle-free, microneedle patches, intranasal/oral) (HLAAAEAF), Connected Therapeutics & Smart Drug Delivery Monitoring (HLACAFAL)

Keywords

• Microchannel drug delivery
• Intradermal injection technology
• Botulinum toxin therapeutics
• Medical aesthetic devices
• Personalized medicine platform

Headquarters

HQ city

New York

HQ country

United States

HQ region

North America

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Marketing or Sales, Supply Chain, Personnel, Operations

Revenue model

1. Commercial Products Sales: Aquavit generates revenue from commercialized products including AQUAGOLD® fine touch (AQT-001) which is sold to medical professionals. The company also has additional commercial products in the pipeline such as MICROTOX™ and MICROFILL™. Revenue is derived from selling medical devices and related consumables/products to physicians and aesthetic practitioners.
2. Licensing & Commercialization Rights: Aquavit in-licenses botulinum toxin assets (DTX-021) and licenses out its technology platforms. The company holds exclusive licenses to register, market, and commercialize products in specific territories (e.g., botulinum toxin in US and Canada). Licensing and royalty arrangements support revenue generation.
3. Pharmaceutical Pipeline Products: Pipeline products including DTX-021, DTX-023, DTX-024, and others are under clinical development. Aquavit pursues FDA approvals and plans to commercialize through standard pharmaceutical sales channels upon regulatory clearance. Revenue expected from both aesthetic and therapeutic indications.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

Aquavit Pharmaceuticals develops and commercializes a patented microchannel drug delivery platform that enables painless intradermal administration of drugs, biologics, vaccines, and cosmetic therapeutics. Its core commercial product is the AQUAGOLD® fine touch (AQT-001) microchannel mesotherapy device, sold to aesthetic physicians and dermatologists, alongside an in-licensed botulinum toxin asset (DTX-021 / Dermatox™) and an AI-integrated smart compounding system (APOLLO® / PITO-001). The pipeline spans medical aesthetics, dermatology, neuroscience, immunology, and oncology applications.

Product overview

Aquavit Pharmaceuticals offers a diversified portfolio of pharmaceutical, biotech, and medical device technologies centered on its patented microchannel drug delivery platform. The core technology enables painless, efficient intradermal delivery of drugs, biologics, and therapeutic agents with minimized systemic toxicity. Key products include AQUAGOLD® fine touch™ (AQT-001) as the commercialized microchannel mesotherapy device, DTX-021 and Dermatox™ (aqubotulinumtoxinA) as botulinum toxin injectables, APOLLO® (PITO-001) as the AI-integrated smart compounding platform, and AQUABELO™ (AQV-001) for HA-based dermal filling. The pipeline includes DTX-023 and DTX-024 for hyperhidrosis treatment, iMicrotox™ and Microtox™ for periorbital and general botulinum delivery, AQV-1122 for epidermal vaccine delivery, and ACK-122/BCC-903 for skin cancer treatment. The architecture combines a unified microchannel delivery technology platform with multiple product form factors and therapeutic applications across medical aesthetics, dermatology, neuroscience, immunology, and oncology.

Differentiator

Problem solved

Functional benefit

Brands

• AQUAGOLD® fine touch™: Commercial microchannel mesotherapy device for delivering therapeutic agents to address skin conditions.
• Dermatox™
• AQUABELO™
• APOLLO®
• Microtox™
• iMicrotox™
• A.S.A.P!™
• SKINWORKOUT™

Products and services

• AQUAGOLD® fine touch™ (AQT-001) Commercial microchannel mesotherapy device that delivers drugs or biologics directly into the skin at approximately 2,000 microinjections per minute. Sold to aesthetic physicians, dermatologists, and plastic surgeons for personalized in-office treatments addressing skin quality, fine lines, and other dermatologic concerns.
• DTX-021 (AqubotulinumtoxinA) Injectable neuromodulator derived from neurotoxins produced by Clostridium botulinum that inhibits neurotransmission between peripheral nerve endings and muscle fibers. In-licensed by Aquavit for the US and Canada, with completed Phase III clinical trials showing equivalency to onabotulinumtoxinA (BOTOX®) on glabellar lines and improvement on periorbital rhytids.
• Dermatox™ (aqubotulinumtoxinA) Flag intradermal injection of botulinum toxin (aqubotulinumtoxinA) for temporary improvement of mild to moderate face and neck lines and skin quality in adults. Pursuing first-ever FDA approval for intradermal botulinum toxin injection for skin quality improvement.
• APOLLO® (PITO-001) First-of-its-kind smart desktop compounding technology combining patented microchannel meso technology for interdermal delivery with AI integration and a MAV-series big data platform. Functions as a micro-injector for comprehensive personalized medicine; patented in US, Europe, and Korea.
• AQUABELO™ (AQV-001 / Microfill HA™) Patented freeze vacuum dried Hyaluronic Acid crystal balls designed for intradermal and interdermal delivery via AQT-004 microchannel technology. Enables site-specific injection of HA for dermal filling applications.
• Microtox™ (AQT-004) Unique low-dose microchannel microinjector that delivers botulinum toxin via patented microchannel technology. Designed for general botulinum toxin administration; pending FDA clearance for commercial use.
• iMicrotox™ (AQB-121) Unique low-dose microchannel microinjector that delivers botulinum toxin to the periorbital region via patented microchannel technology. Forecasted to capture 10-20% of the global botulinum toxin market; pending FDA clearance.
• ACK-122 / BCC-903 Drug delivery technology addressing Actinic Keratosis (AK) and Basal Cell Carcinoma (BCC) skin cancer. Delivers high-dosage efficacious compounds directly into the skin with minimal adverse reactions to address tolerability, patient compliance, and persistency issues.
• AQV-1122 Epidermal Vaccine Delivery Device Single-use epidermal drug delivery device for self-administration of biologics, drugs, and vaccines using a patented screw-thread microchannel delivery apparatus. Targets the epidermis/papillary dermis to leverage abundant Langerhans cells for improved immune response.
• DTX-023 Botulinum toxin on biosimilar pathway to onabotulinumtoxinA. FDA IND cleared for Phase II/III S.W.E.A.T. I™ trial for primary axillary hyperhidrosis.
• DTX-024 AqubotulinumtoxinA formulation combined with AQT intradermal microinjector. FDA IND cleared for Phase II/III S.W.E.A.T. II™ trial for palmar hyperhidrosis; first intradermal botulinum toxin therapy pursued for this indication.
• Smart Skin Analyzer Platform First-of-its-kind smart skin analyzer platform integrated with the APOLLO AI and big data platform to support personalized dermatology and aesthetic treatment planning.

Quantifiable outcome

• iMicrotox™ (AQB-121) is forecasted to capture 10-20% of the current global botulinum toxin market.
• +3 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature10 records

Partnerships

Two partnerships are on record, tiered core.

• Axon Technologies AGcoreStrategic or Co-development Partner · 23 September 2025Aquavit Pharmaceuticals AG acquired Axon Technologies AG on September 23, 2025, enhancing its AI and life-science capabilities. The acquisition involved integration of AI-driven drug development and healthcare solutions. This strategic acquisition strengthens Aquavit's technology portfolio by adding AI capabilities to its drug delivery and healthcare platforms.
• Dassault Systemes (Accelrys)coreTechnology or IntegrationBig data platform licensing agreement with Dassault Systemes (Accelrys) signed in 2013. The agreement provided Aquavit access to advanced big data analytics and simulation platforms to support its drug development and personalized medicine initiatives.

Scale indicators7 records

Recent moves11 records

Expansion highlights7 records

Broad incumbents

• Galderma: Global dermatology and aesthetics leader with a portfolio that includes aesthetic injectables, dermatology therapeutics, and skin care. Competes with Aquavit across the dermatology/aesthetic intersection and pursues novel neuromodulator and dermal filler offerings.
• Allergan Aesthetics (AbbVie): Markets BOTOX® (onabotulinumtoxinA), the dominant global botulinum toxin and the direct standard-of-care comparator to Aquavit's DTX-021, DTX-023, DTX-024, Microtox, and iMicrotox. AbbVie's aesthetic franchise makes it the most relevant incumbent peer across both aesthetic and therapeutic neuromodulator indications.
• Merz Aesthetics: Markets Xeomin® (incobotulinumtoxinA) and Radiesse® as part of a broader aesthetic portfolio. Directly comparable to Aquavit in both neuromodulator competition and aesthetic dermal filler categories where AQUABELO™ competes.

Direct peers

• Evolus: Markets Jeuveau® (prabotulinumtoxinA), a competing aesthetic neuromodulator directly targeting the same cosmetic indication (glabellar lines) as Aquavit's DTX-021 and Dermatox™. Pure-play aesthetic neuromodulator focus makes it a tightly comparable direct peer.
• Revance Therapeutics: Markets DAXXIFY® (daxibotulinumtoxinA) for aesthetic and therapeutic indications including glabellar lines and cervical dystonia. Directly comparable to Aquavit's pipeline in both neuromodulator modality and aesthetic/therapeutic dual positioning, with overlapping R&D strategy around novel botulinum toxin formulations.
• Hugel: South Korean botulinum toxin manufacturer (Botulax/Letybo) competing in the same global neuromodulator market as Aquavit's DTX-021. Particularly relevant given Aquavit's South Korean manufacturing footprint and overlapping regulatory approvals in Asian markets.
• Medytox: South Korean botulinum toxin maker (Neuronox) operating in the same neuromodulator category as Aquavit. Comparable pipeline focus on botulinum toxin applications and same regional manufacturing base in South Korea.

Emerging players

• BTL Aesthetics: Medical device company selling aesthetic treatment platforms (body contouring, skin tightening) to physicians and medspas. Comparable to Aquavit in the B2B physician-channel go-to-market and in delivering hardware-based aesthetic solutions to dermatologists and plastic surgeons.
• Crown Laboratories: Aesthetics and skincare company with both consumer (SkinPen microneedling) and prescription aesthetics portfolios. Comparable to Aquavit in aesthetic medical device/drug delivery strategy and in physician-channel distribution.

Regional players

• Croma-Pharma: Aesthetic medicine company focused on hyaluronic acid fillers, botulinum toxin, and related injectables primarily in European markets. Comparable to Aquavit in the HA filler category where AQUABELO™ competes, and in pursuing injectable aesthetics innovations.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xtwitter.com/aquavitpharma?lang=en
• Facebookfacebook.com/AquavitPharma
• LinkedInlinkedin.com/company/aquavit-pharmaceuticals-inc

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Subsidiaries3 records

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Aquavit Pharmaceuticals